TY - JOUR T1 - <em>R</em>(+)-8-OH-DPAT, a Serotonin<sub>1A</sub> Receptor Agonist, Potentiated <em>S</em>(−)-Sulpiride-Induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens But Not Striatum JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 1227 LP - 1232 VL - 291 IS - 3 AU - Junji Ichikawa AU - Herbert Y. Meltzer Y1 - 1999/12/01 UR - http://jpet.aspetjournals.org/content/291/3/1227.abstract N2 - The serotonin (5-HT)2A/2C receptor antagonist ritanserin has been reported to potentiate the dopamine (DA) D2/3receptor antagonist raclopride-induced DA release in medial prefrontal cortex (mPFC) and nucleus accumbens (NAC) but not striatum (STR). Because of reciprocal interactions between 5-HT2A and 5-HT1A receptors, we tested the hypothesis that 5-HT1A receptor agonism also potentiates D2/3 receptor antagonist-induced DA release using a combination of the 5-HT1A receptor agonistR(+)-8-hydroxy-2-(di-n-propylamino)-tetralin [R(+)-8-OH-DPAT] and the D2/3 receptor antagonist S(−)-sulpiride (SUL).R(+)-8-OH-DPAT (0.05 mg/kg s.c.) potentiated low but not high dose SUL (1, 3 but not 10 or 25 mg/kg s.c.)-induced DA release in NAC, but had no effect in STR at all doses tested (1, 3, 10, and 25 mg/kg s.c.). However, R(+)-8-OH-DPAT (0.05 mg/kg s.c.) alone had no effect on basal, potentiated SUL (10 and 25 mg/kg s.c.)-induced DA release in mPFC; the effect of low dose SUL (1 and 3 mg/kg s.c.) was not tested because it alone had no effect on DA release. This potentiation was abolished by pretreatment with the 5-HT1A receptor antagonist WAY100635 (0.05 mg/kg s.c.), which alone had no effect on DA release. These results suggest that 5-HT1A receptor agonism facilitates DA release in mPFC and NAC but not STR in combination with D2 receptor antagonism. The American Society for Pharmacology and Experimental Therapeutics ER -